Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
NCT07149363
This study is recruiting at 6 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Small Cell Lung Cancer (SCLC)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Alliance Foundation Trials, LLC.
- Last updated on ClinicalTrials.gov
- October 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Illinois · 1
- University of Illinois Chicago · Chicago, IL
Maine · 1
- Maine Medical Center · Scarborough, ME
Massachusetts · 2
- Dana Farber Cancer Institute · Boston, MA
- Massachusetts General Hospital (MGH) · Boston, MA
Missouri · 1
- Washington University in St. Louis School of Medicine · St Louis, MO
Virginia · 1
- University of Virginia Comprehensive Cancer Center · Charlottesville, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.